Citi analyst Patrick Donnelly downgraded Bruker (BRKR) to Neutral from Buy with a price target of $40, down from $50. The company’s exposure to the U.S. academic and government market may lead to order volatility which may linger into 2026, the analyst tells investors in a research note. The firm says that even if the National Institutes of Health budget cut comes in lighter than expected, academic and research institutions will remain more cautious on spending. Citi is more cautious on forward years than the recent share price decline suggests.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRKR:
- 10x Genomics price target lowered to $18 from $26 at Morgan Stanley
- Bruker’s Legal Settlement Boosts Investor Confidence and Supports Buy Rating
- Bruker Announces Settlement with 10x Genomics
- 10x Genomics announces patent litigation settlement with Bruker
- Bruker, 10x Genomics reach final settlement to resolve patent disputes
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue